SARS-CoV-2 Vaccines Beyond the Pandemic Era

Deep learning analysis of long COVID and vaccine impact in low- and middle-income countries (LMICs): development of a risk calculator in a multicentric study

• Ahmed Shaheen
• Nour Shaheen
• Long COVID Collaboration Study Group in the LMICs
• Sheikh Shoib
• Fahimeh Saeed
• Mudathiru Buhari
• Vishal Bharmauria
• Oliver Flouty

Fc-effector functional antibody assays for SARS-CoV-2 variants of concern

• Xuemin Chen
• Grace Li
• Caroline Ciric
• Theda Gibson
• Larry J. Anderson
• Christina A. Rostad

Retraction: Evaluation of post-COVID mortality risk in cases classified as severe acute respiratory syndrome in Brazil: a longitudinal study for medium and long term

Commentary: Evaluation of post-COVID mortality risk in cases classified as severe acute respiratory syndrome in Brazil: a longitudinal study for medium and long term

• Rubens C. Costa-Filho
• José Paulo G. Leite
• Marco Aurélio Horta
• Felipe Gomes Naveca
• Felipe Saddy
• Hugo C. Castro de Faria Neto

Commentary: Evaluation of post-COVID mortality risk in cases classified as severe acute respiratory syndrome in Brazil: a longitudinal study for medium and long term

• Raphael Mendonça Guimarães
• Christovam Barcellos
• Renata Gracie
• Diego Ricardo Xavier
• Marcel de Moraes Pedroso
• Monica de Avellar Figueiredo Mafra Magalhães

Vaccination with inactivated SARS-CoV-2 vaccine TURKOVAC induces durable humoral and cellular immune responses up to 8 months

• Seçil Yılmaz
• Ahmet Eken
• Zafer Sezer
• Burcu Şen Bağcı
• Serife Erdem
• Medine Doğan Sarıkaya
• Busra Kaplan
• Ahmet Inal
• Adnan Bayram
• 8 more
• Aykut Ozdarendeli

COVID-19 inactivated booster vaccines elicit strong protection against SARS-CoV-2 wild-type and Omicron variant in patients with breast cancer

• Xiaomeng Li
• Yali Xu
• Haolong Li
• Linrong Li
• Yongmei Liu
• Haoting Zhan
• Qiang Sun
• Yongzhe Li

Impact of QazVac vaccination on clinical manifestations and immune responses in post—COVID syndrome: a cross-sectional study

• Akzhan M. Madenbayeva
• Saulesh S. Kurmangaliyeva
• Saltanat T. Urazayeva
• Kairat B. Kurmangaliyev
• Yerlan Sh. Bazargaliyev
• Khatimya I. Kudabayeva

Enhanced T-cell immunity and lower humoral responses following 5-dose SARS-CoV-2 vaccination in patients with inborn errors of immunity compared with healthy controls

• Vitor Gabriel Lopes da Silva
• Gabriela Justamante Händel Schmitz
• Kathleen E. Sullivan
• Júlia Barbate
• Maria Izabel de Haro Azinar
• Carolina Sanchez Aranda
• Maria Isabel de Moraes-Pinto

Assessment of serum biomarker changes following the COVID-19 pandemic and vaccination: a cohort study in Sylhet, Bangladesh

• Shangida Akther
• Fairoz Samiha
• Sabrina Amita Sony
• Mohammad Anamul Haque
• Mohammad Abul Hasnat
• S. M. Saiful Islam
• Shamim Ahmed
• Mohammad Abdullah-Al-Shoeb

Follow-up of humoral and cellular immune responses after the third SARS-CoV-2 vaccine dose in multiple myeloma patients

• Vincenzo Raimondi
• Paola Storti
• Rosanna Vescovini
• Valentina Franceschi
• Denise Toscani
• Laura Notarfranchi
• Anna Benedetta Dalla Palma
• Nicolas Thomas Iannozzi
• Sergio Minesso
• 4 more
• Nicola Giuliani

XBB.1.5 mRNA COVID-19 vaccine protection against inpatient or emergency department visits among adults infected with SARS-CoV-2 JN.1 and XBB-lineage variants

• Matthew E. Levy
• Vanessa Chilunda
• Phillip R. Heaton
• Deran McKeen
• Jason D. Goldman
• Richard E. Davis
• Cynthia A. Schandl
• William B. Glen
• Lisa M. McEwen
• 13 more
• Shishi Luo